Susan G R McDuff1, Amir I Mina2, Cheryl L Brunelle3, Laura Salama2, Laura E G Warren4, Mohamed Abouegylah2, Meyha Swaroop2, Melissa N Skolny2, Maria Asdourian2, Tessa Gillespie2, Kayla Daniell2, Hoda E Sayegh2, George E Naoum2, Hui Zheng5, Alphonse G Taghian6. 1. Department of Radiation Oncology, Massachusetts General Hospital, Harvard Medical School, Boston, Massachusetts; Harvard Radiation Oncology Program, Harvard Medical School, Boston, Massachusetts. 2. Department of Radiation Oncology, Massachusetts General Hospital, Harvard Medical School, Boston, Massachusetts. 3. Department of Physical and Occupational Therapy, Massachusetts General Hospital, Boston, Massachusetts. 4. Department of Radiation Oncology, Brigham and Women's Hospital, Harvard Medical School, Boston, Massachusetts. 5. Department of Biostatistics, Massachusetts General Hospital, Boston, Massachusetts. 6. Department of Radiation Oncology, Massachusetts General Hospital, Harvard Medical School, Boston, Massachusetts. Electronic address: ataghian@partners.org.
Abstract
PURPOSE: The purpose of the study was to determine when the risk of lymphedema is highest after treatment of breast cancer and which factors influence the time course of lymphedema development. METHODS AND MATERIALS: Between 2005 and 2017, 2171 women (with 2266 at-risk arms) who received surgery for unilateral or bilateral breast cancer at our institution were enrolled. Perometry was used to objectively assess limb volume preoperatively, and lymphedema was defined as a ≥10% relative arm-volume increase arising >3 months postoperatively. Multivariable regression was used to uncover risk factors associated with lymphedema, the Cox proportional hazards model was used to calculate lymphedema incidence, and the semiannual hazard rate of lymphedema was calculated. RESULTS: With a median follow-up of 4 years, the overall estimated 5-year cumulative incidence of lymphedema was 13.7%. Significant factors associated with lymphedema on multivariable analysis were high preoperative body mass index, axillary lymph node dissection (ALND), and regional lymph node radiation (RLNR). Patients receiving ALND with RLNR experienced the highest 5-year rate of lymphedema (31.2%), followed by those receiving ALND without RLNR (24.6%) and sentinel lymph node biopsy with RLNR (12.2%). Overall, the risk of lymphedema peaked between 12 and 30 months postoperatively; however, the time course varied as a function of therapy received. Early-onset lymphedema (<12 months postoperatively) was associated with ALND (HR [hazard ratio], 4.75; P < .0001) but not with RLNR (HR, 1.21; P = .55). In contrast, late-onset lymphedema (>12 months postoperatively) was associated with RLNR (HR, 3.86; P = .0001) and, to a lesser extent, ALND (HR, 1.86; P = .029). The lymphedema risk peaked between 6 and 12 months in the ALND-without-RLNR group, between 18 and 24 months in the ALND-with-RLNR group, and between 36 and 48 months in the group receiving sentinel lymph node biopsy with RLNR. CONCLUSIONS: The time course for lymphedema development depends on the breast cancer treatment received. ALND is associated with early-onset lymphedema, and RLNR is associated with late-onset lymphedema. These results can influence clinical practice to guide lymphedema surveillance strategies and patient education.
PURPOSE: The purpose of the study was to determine when the risk of lymphedema is highest after treatment of breast cancer and which factors influence the time course of lymphedema development. METHODS AND MATERIALS: Between 2005 and 2017, 2171 women (with 2266 at-risk arms) who received surgery for unilateral or bilateral breast cancer at our institution were enrolled. Perometry was used to objectively assess limb volume preoperatively, and lymphedema was defined as a ≥10% relative arm-volume increase arising >3 months postoperatively. Multivariable regression was used to uncover risk factors associated with lymphedema, the Cox proportional hazards model was used to calculate lymphedema incidence, and the semiannual hazard rate of lymphedema was calculated. RESULTS: With a median follow-up of 4 years, the overall estimated 5-year cumulative incidence of lymphedema was 13.7%. Significant factors associated with lymphedema on multivariable analysis were high preoperative body mass index, axillary lymph node dissection (ALND), and regional lymph node radiation (RLNR). Patients receiving ALND with RLNR experienced the highest 5-year rate of lymphedema (31.2%), followed by those receiving ALND without RLNR (24.6%) and sentinel lymph node biopsy with RLNR (12.2%). Overall, the risk of lymphedema peaked between 12 and 30 months postoperatively; however, the time course varied as a function of therapy received. Early-onset lymphedema (<12 months postoperatively) was associated with ALND (HR [hazard ratio], 4.75; P < .0001) but not with RLNR (HR, 1.21; P = .55). In contrast, late-onset lymphedema (>12 months postoperatively) was associated with RLNR (HR, 3.86; P = .0001) and, to a lesser extent, ALND (HR, 1.86; P = .029). The lymphedema risk peaked between 6 and 12 months in the ALND-without-RLNR group, between 18 and 24 months in the ALND-with-RLNR group, and between 36 and 48 months in the group receiving sentinel lymph node biopsy with RLNR. CONCLUSIONS: The time course for lymphedema development depends on the breast cancer treatment received. ALND is associated with early-onset lymphedema, and RLNR is associated with late-onset lymphedema. These results can influence clinical practice to guide lymphedema surveillance strategies and patient education.
Authors: Chirag Shah; John Ben Wilkinson; Andrew Baschnagel; Mihai Ghilezan; Justin Riutta; Nayana Dekhne; Savitha Balaraman; Christina Mitchell; Michelle Wallace; Frank Vicini Journal: Int J Radiat Oncol Biol Phys Date: 2011-11-16 Impact factor: 7.038
Authors: Timothy J Whelan; Ivo A Olivotto; Wendy R Parulekar; Ida Ackerman; Boon H Chua; Abdenour Nabid; Katherine A Vallis; Julia R White; Pierre Rousseau; Andre Fortin; Lori J Pierce; Lee Manchul; Susan Chafe; Maureen C Nolan; Peter Craighead; Julie Bowen; David R McCready; Kathleen I Pritchard; Karen Gelmon; Yvonne Murray; Judy-Anne W Chapman; Bingshu E Chen; Mark N Levine Journal: N Engl J Med Date: 2015-07-23 Impact factor: 91.245
Authors: Jeffrey M Straub; Jacob New; Chase D Hamilton; Chris Lominska; Yelizaveta Shnayder; Sufi M Thomas Journal: J Cancer Res Clin Oncol Date: 2015-04-25 Impact factor: 4.553
Authors: Ravi A Chandra; Cynthia L Miller; Melissa N Skolny; Laura E G Warren; Nora Horick; Lauren S Jammallo; Betro T Sadek; Mina N Shenouda; Jean O'Toole; Michelle C Specht; Alphonse G Taghian Journal: Int J Radiat Oncol Biol Phys Date: 2015-03-15 Impact factor: 7.038
Authors: X Allen Li; An Tai; Douglas W Arthur; Thomas A Buchholz; Shannon Macdonald; Lawrence B Marks; Jean M Moran; Lori J Pierce; Rachel Rabinovitch; Alphonse Taghian; Frank Vicini; Wendy Woodward; Julia R White Journal: Int J Radiat Oncol Biol Phys Date: 2009-03-01 Impact factor: 7.038
Authors: Victor Domingos Lisita Rosa; Angela Adamski da Silva Reis; Rafael Ribeiro Alves; Caroline Souza Dos Anjos; Ruffo Freitas-Junior Journal: Support Care Cancer Date: 2021-09-16 Impact factor: 3.359
Authors: Rachelle Crescenzi; Paula M C Donahue; Maria Garza; Chelsea A Lee; Niral J Patel; Victoria Gonzalez; R Sky Jones; Manus J Donahue Journal: Breast Cancer Res Treat Date: 2021-10-23 Impact factor: 4.624
Authors: Loryn K Bucci; Cheryl L Brunelle; Madison C Bernstein; Amy M Shui; Tessa C Gillespie; Sacha A Roberts; George E Naoum; Alphonse G Taghian Journal: Ann Surg Oncol Date: 2021-06-11 Impact factor: 5.344
Authors: Yara W Kassamani; Cheryl L Brunelle; Tessa C Gillespie; Madison C Bernstein; Loryn K Bucci; Tracy Nassif; Alphonse G Taghian Journal: Ann Surg Oncol Date: 2021-09-09 Impact factor: 5.344
Authors: Kelly M Herremans; Morgan P Cribbin; Andrea N Riner; Dan W Neal; Tracy L Hollen; Pamela Clevenger; Derly Munoz; Shannon Blewett; Fantine Giap; Paul G Okunieff; Nancy P Mendenhall; Julie A Bradley; William M Mendenhall; Raymond B Mailhot-Vega; Eric Brooks; Karen C Daily; Coy D Heldermon; Julia K Marshall; Mariam W Hanna; Mark M Leyngold; Sarah S Virk; Christiana M Shaw; Lisa R Spiguel Journal: Ann Surg Oncol Date: 2021-08-07 Impact factor: 5.344
Authors: Sacha A Roberts; Tessa C Gillespie; Amy M Shui; Cheryl L Brunelle; Kayla M Daniell; Joseph J Locascio; George E Naoum; Alphonse G Taghian Journal: Cancer Date: 2021-07-27 Impact factor: 6.860